MedPath

Effect of SLN containing finasteride on anderogenic alopecia

Phase 2
Conditions
anderogenic alopecia.
Androgenic alopecia
Registration Number
IRCT20181128041780N1
Lead Sponsor
Mashhad University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Male
Target Recruitment
50
Inclusion Criteria

Men with Androgenic Alopecia Based on Hamilton's Criteria. Stage 2-4
Completing the consent form

Exclusion Criteria

No endocrine disease (diabetes), thyroid disorders, systemic diseases including lupus, other cases, including arthritis and cicatrisil (associated with scar), history of skin or systemic malignancy, psychiatric disorders, skin disorders Head skulls other than those with AGASerious Cardiovascular Diseases, Kidney Disease, Liver Disease
No use of zinc and iron supplements, malnutrition, iron deficiency anemia
Non-use of medications leads to hair loss, including anti-hypertensive and anti-inflammatory drugs, NSAIDs
No history of alcohol consumption or substance abuse
No history of finasteride in the last 6 months and minoxidil in the past month
No history of drug hypersensitivity, breast disorders, surgical history for the treatment of hair loss

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The number of hair from short hair in 1 cm square in the area of assessment in the Vertex hairless part. Timepoint: At the beginning of the work and weeks 8, 16 and 24. Method of measurement: Using the computer scan obtained from macrophotography images of the marked area, it is evaluated for hair growth.
Secondary Outcome Measures
NameTimeMethod
1- Evaluation of the frequency of local skin complications including: erythema-burning-itchy-folliculitis-clinical diagnosis by the assessor. Timepoint: At the beginning of the work and weeks 8, 16 and 24. Method of measurement: 1-Measuring erythema and itching and burning with a visual analogue scale and evaluating folliculitis clinically and by assessor.;2. Quality of life assessment. Timepoint: At the beginning of the work and weeks 8, 16 and 24. Method of measurement: 2. Assessing the quality of life ,the basis of the WAA-QOL benchmark.
© Copyright 2025. All Rights Reserved by MedPath